Act now to improve the health of women, children and adolescents worldwide, say experts

Societies are failing women, children and adolescents, particularly in the poorest communities around the world, and urgent action is needed to save lives and improve health, say global health experts. In a special supplement published today by The BMJ, public health experts from around the globe highlight the critical actions and investments that will have the greatest impact on the health and well-being of women, children and adolescents.

The 15 papers in this special supplement outline the current evidence, identify successes as well as critical gaps in progress, and highlight key priorities to end preventable deaths and ensure that women, children and adolescents can thrive and build resilient and prosperous societies.

Dr Marleen Temmerman, Director of WHO Department of Reproductive Health and Research including HRP, and one of the lead authors of the special supplement states, "Clearly business as usual will not work. For women, children and adolescents around the world to survive, thrive and transform our current society to arrive at the future we want, we need radical actions that will result in enormous social, demographic, and economic benefits."

Although great strides have been made in reducing child and maternal mortality by 53% and over 40%[1] respectively since 1990, the authors explain how many more lives can be saved by improving access to essential health interventions.

Vast inequities within and between countries mean that the poorest, most disadvantaged women, children, and adolescents often miss out on life-saving health services and experience serious violations of their human rights.

Some low- and middle-income countries have:

  • Up to three times more pregnancies among teenage girls in rural and indigenous populations than in urban populations
  • A difference of up to 80% between the richest and poorest people in the proportion of births attended by skilled health personnel
  • A gap of at least 18% in the proportion who seek care for children with pneumonia symptoms, between the poorest and richest people and
  • A difference of least 25% in access to antenatal care (of at least four visits) between the most and least educated and between the richest and poorest.

"No woman, child or adolescent should face a greater risk of preventable death just because of where they live," says Dr Flavia Bustreo, Assistant Director-General of the World Health Organization. "We know what needs to be done. With the existing evidence, we now have the opportunity to end preventable deaths among all women, children, and adolescents, to vastly improve their health, and to bring about the transformative changes needed to fully realise their human rights and build resilient and prosperous societies."

The papers published today provide the evidence that has helped inform the development of a new Global Strategy for Women's, Children's and Adolescents' Health, which will be launched at the United Nations General Assembly in New York on 26 September 2015.

As the deadline for the United Nations' Millennium Development Goals approaches, countries have come together to agree upon a new set of development goals, which will be launched also in New York this month. The survival, health and well-being of women, children and adolescents is at the heart of this agenda, and the new Global Strategy to prevent deaths and improve the health of millions of women, children and adolescents will provide a platform for the achievement of these new goals.

The new Global Strategy builds on new evidence and lessons learnt. It focuses on reaching everyone, in particular critical population groups many of whom live in humanitarian and fragile settings - where a majority of these deaths happen.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...